2023-07-07 11:13:41
Protyon Collaborates with Open Diagnostics Ecosystem to Develop Personalized Treatment Software for Lung Cancer Patients
Protyon, a health tech start-up based in Groningen, has embarked on a new learning project in collaboration with the Open Diagnostics Ecosystem (ODE) to develop software that can provide personalized treatment options for lung cancer patients. The software, which utilizes molecular modeling of unknown cancer mutations, aims to revolutionize the way lung cancer is treated.
With a subsidy of over 92,000 euros from ODE, the project officially commenced on 1 May and is scheduled to run until October 2023. Protyon is collaborating with the University Medical Center Groningen (UMCG), the University of Groningen (RUG), and Researchable, a local software development and data company.
The technology behind Protyon’s software involves creating a 3D model of mutated proteins based on the genetic code of the mutation. This enables physicians to analyze the effectiveness of different treatment options and tailor personalized therapies for each patient. Lung cancer often presents new mutations throughout the course of the disease, rendering previously chosen treatments ineffective. Protyon’s software aims to address this challenge and provide physicians with a valuable tool for navigating treatment decisions.
The company’s name, Protyon, is a clever contraction of “Procyon” and “protein.” Procyon refers to a bright star that has historically served as a navigational point for sailors. Rositsa Jordanova, CEO of Protyon, explains, “The combination sums up our mission: to be a navigator for physicians working to fight protein-driven diseases.”
CEO Rositsa Jordanova also acknowledges the crucial role played by researchers and doctors at RUG and UMCG in the development of this software. She highlights the pioneering work of the MTB Groningen, a platform for implementing personalized treatment plans for rare and complex molecular changes in cancer patients. The UMCG is the only hospital currently applying molecular modeling in the treatment of lung cancer, making them game changers in the field.
Protyon was founded in 2022 as a spin-out of the University of Groningen and the UMCG Innovation Center. The company specializes in developing software that enables clinicians to create personalized therapy options for lung cancer patients based on molecular modeling of mutations. The UMCG Innovation Center supports healthcare professionals and researchers within and outside the UMCG in turning their innovations into successful ventures.
For more information about Protyon and its innovative software, please visit their website at www.protyon.tech.]
#Protyon #Groningen #develops #software #treatment #lung #cancer